Search PubMed⌕ Search

Biomedical subjects

M Rabuffetti

Publications and source records attributed to M Rabuffetti.

25 records · Page 2Linked to original sources
PubMed1999

Validation protocol of models for centre of mass estimation.

The estimation of the body centre-of-mass (COM) position requires the modelling of the human body as a system of rigid segments and the measurement of the position of related external anatomical landmarks. Many models for COM position estimation have been proposed with different levels of complexity and, in some cases, specific protocols have been used for model accuracy evaluation. In this paper, we propose a general method for the quantitative assessment of any COM model in relation to a determined set of movements. It consists of an experimental protocol and of a set of comparative indices, which quantify the congruence among the estimated kinematic variables and their expected values. The general applicability of the method is specifically addressed to models' comparison, aiming to support the user in the process of choice and validation of the most suitable model for her/his purposes. In this frame, the results of the analytical comparison among two kinematic models with different levels of complexity are reported.

Algorithms↗
PubMed1998

Multifactorial estimation of hip and knee joint centres for clinical application of gait analysis.

Estimation of joint centres is required in gait analysis for kinematic and kinetic elaboration. In general, the method is based on regression equations and palpation of bone prominences. A kinematic approach can also be used at the hip joint but appears to be more demanding for the patients. The method presented here combines different independent approaches and is aimed at reducing the estimation errors caused by from skin motion artefacts and statistical variance of anthropometric data. It is based on minimising an optimisation function in which data from gait kinematics, anthropometric measurements and statistically derived morphological parameters are properly weighted. The procedure is suitable for clinical applications where the range of motion might be reduced and the patients can not perform complicated exercises. Validation has been made on ten normal subjects and ten patients with spina bifida. The results show that the reproducibility of the estimation and the congruency with the external measurements is improved with respect to both the morphologically based approach and the kinematic method. Copyright 1998 Elsevier Science B.V.

Journal Article↗
PubMed1998

Functionally oriented and clinically feasible quantitative gait analysis method.

A protocol for clinical gait analysis is described, and data from 30 normal adult female subjects are presented. Extensive application to pathologic subjects has proven to be feasible and sufficiently accurate. The method is based on a particular location and attachment of retro-reflective markers on the body and on a particular arrangement of four TV cameras. A motion analyser measures the 3D coordinates of each marker. A modelling approach, based on individual anthropometric measurements, and a functional approach, based on kinematical considerations, are used to estimate the location of hip, knee, and ankle joint centers and the orientation of the flexion-extension axis of the knee. 3D relative and absolute movements of pelvis and lower limbs are obtained and shown to be consistent with functional anatomy.

Adult↗
PubMed1998

Transient expression of the 5alpha-reductase type 2 isozyme in the rat brain in late fetal and early postnatal life.

The enzyme 5alpha-reductase plays a key role on several brain functions controlling the formation of anxiolytic/anesthetic steroids derived from progesterone and deoxycorticosterone, the conversion of testosterone to dihydrotestosterone, and the removal of excess of potentially neurotoxic steroids. Two 5alpha-reductase isoforms have been cloned: 5alpha-reductase type 1 is widely distributed in the body, and 5alpha-reductase type 2 is confined to androgen-dependent structures. In this study, the gene expression of the two 5alpha-reductase isozymes has been analyzed in fetal, postnatal, and adult rat brains by RT-PCR followed by Southern analysis. 5Alpha-reductase type 1 messenger RNA is always detectable in the rat brain [from gestational day 14 (GD14) to adulthood]. 5Alpha-reductase type 2 messenger RNA expression is undetectable on GD14, increases after GD18, peaks on postnatal day 2, then decreases gradually, becoming low in adulthood. This pattern of expression appears to be correlated with the rate of production of testosterone by the testis. The possible control by androgens of gene expression of the two isozymes has been studied in brain tissues of animals exposed in utero to the androgen antagonist flutamide; the sex of the animals was determined by genetic sex screening of the SRY gene located on the Y-chromosome. In the brain of male embryos, flutamide treatment inhibited the expression of 5alpha-reductase type 2; this effect was much less pronounced in females. Moreover, 5alpha-reductase type 2 gene expression in cultured hypothalamic neurons is highly induced by testosterone and by the phorbol ester 12-O-tetradecanoyl-phorbol-13 acetate. The transient, androgen-regulated, expression of 5alpha-reductase type 2 overlaps the critical period of development, which may be important for sexual differentiation of the brain and for the formation of anxiolytic/anesthetic steroids involved in the stress responses associated with parturition.

3-Oxo-5-alpha-Steroid 4-Dehydrogenase↗
PubMed1997

Identification of type 1 5alpha-reductase in myelin membranes of male and female rat brain.

The formation of the 5alpha-reduced metabolites of testosterone (T) and of progesterone (P) is a very active process in the brain, since the enzyme 5alpha-reductase (5alpha-R) is present in almost any central nervous system (CNS) structure. A particularly elevated 5alpha-R activity has been shown in myelin sheaths. Two isoforms of the enzyme have been cloned, with different localisation as well as different biochemical properties. The present study was performed to determine whether both isoforms of the 5alpha-R, or only one of them, are/is responsible for the enzymatic activity observed in myelin. Kinetic analyses have been performed on purified myelin membranes prepared from the male or female rat brain, using both T and P as substrates. The 5alpha-R present appears to possess a pH optimum at basic values. The Vmax values obtained in the Lineweaver-Burk analysis were comparable in male and female preparations independently on whether T or P were used as the substrates, suggesting that a single enzymatic form is present in all samples examined; the Km obtained using [14C]T (Km: male 1.14 microM; female 1.46 microM) or [14C]P (Km: male 0.5 microM; female 0.64 microM) as substrates, were in good agreement with those obtained for the recombinant type 1 isoform. These data suggest that the type 1 isoform is the most relevant 5alpha-R present in myelin. To confirm this, a new polyclonal antibody was raised against the type 1 5alpha-R enzymatic protein, and used in immunohistochemical studies. The experiments were performed on the optic nerve, a myelinated structure very rich in 5alpha-R activity and the results clearly indicated the presence of a specific type 1 enzyme immunoreactivity in the myelin sheaths of axons.

3-Oxo-5-alpha-Steroid 4-Dehydrogenase↗
PubMedDate not supplied

Cannabinoids and neuroprotection.

Cannabinoid compounds are endowed with pharmacological properties that make them interesting candidates for therapeutic development. These properties have been known since antiquity. However, in the last decade extremely important advances in the understanding of the physiology, pharmacology, and molecular biology of the cannabinoid system have given this field of research fresh impetus and have renewed the interest in the possible clinical exploitation of these compounds. In the present review we summarize the effects elicited, at the cellular level, by cannabinoids acting through receptor-dependent and receptor-independent mechanisms. These data suggest different ways by which cannabinoids may act as neuroprotective agents (prevention of excitotoxicity by inhibition of glutamate release, antioxidant effects, anti-inflammatory actions, etc.). The experimental evidence supporting these hypotheses are presented and discussed with regard to both preclinical and clinical studies in disease states such as cerebral ischemia, brain trauma, and Multiple Sclerosis.

Animals↗